Catalyst
Monitor the trial's progress and results, particularly the primary endpoint of habit adoption and secondary outcomes related to glucose control and quality of life.
Date
June 26, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.